An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kura Oncology, a clinical-stage biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The company aims to advance precision medicines for cancer treatment. A webcast and conference call will be held to discuss the financial results and provide a corporate update.
Kura Oncology, un'azienda biofarmaceutica in fase clinica, comunicherà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024. L'obiettivo dell'azienda è promuovere farmaci di precisione per il trattamento del cancro. Si terrà un webcast e una conferenza telefonica per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Kura Oncology, una empresa biofarmacéutica en etapa clínica, reportará sus resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La empresa tiene como objetivo avanzar en los medicamentos de precisión para el tratamiento del cáncer. Se realizará una webcast y una llamada de conferencia para discutir los resultados financieros y proporcionar una actualización corporativa.
임상 단계의 생물 의약품 회사인 쿠라 온콜로지는 2024년 5월 2일에 2024년 제1분기 재무 결과를 보고할 예정입니다. 이 회사는 암 치료를 위한 정밀 의약품 개발을 목표로 하고 있습니다. 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 웹캐스트와 컨퍼런스 콜이 개최될 예정입니다.
Kura Oncology, une entreprise biopharmaceutique en phase clinique, communiquera ses résultats financiers pour le premier trimestre 2024 le 2 mai 2024. L'entreprise vise à faire avancer les médicaments de précision pour le traitement du cancer. Un webcast et une conférence téléphonique auront lieu pour discuter des résultats financiers et fournir une mise à jour de l'entreprise.
Kura Oncology, ein biopharmazeutisches Unternehmen in der klinischen Phase, wird am 2. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 veröffentlichen. Das Ziel des Unternehmens ist die Weiterentwicklung von Präzisionsmedikamenten zur Krebsbehandlung. Ein Webcast und eine Telefonkonferenz werden abgehalten, um die Finanzergebnisse zu diskutieren und ein Unternehmensupdate zu geben.
Positive
None.
Negative
None.
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia (AML) patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant relapsed/refractory AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors: Pete De Spain Executive Vice President, Investor Relations & Corporate Communications (858) 500-8833 pete@kuraoncology.com
When will Kura Oncology report its first quarter 2024 financial results?
Kura Oncology will report its first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024.
What is Kura Oncology's ticker symbol?
Kura Oncology's ticker symbol is KURA.
How can I access the webcast and conference call discussing Kura Oncology's financial results?
You can access the live call by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay will be available on the company's website.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
